|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
- Accelerate the availability of a first generation artificial pancreas
- Ensure the artificial pancreas and its components are widely available
- Ensure devices from multiple companies are approved and reimbursed,
encouraging investment in next generation technologies
|
|
5
|
|
|
6
|
- Fund Research to
- Test Ways to Create Safe and Effective Artificial Pancreas
- Provide Data to Encourage Health Plan Coverage and Clinician Adoption
of Continuous Glucose Sensors
- Use Communications and Advocacy
Campaigns to
- Ensure Federal Government Makes a Priority
- Speed Regulatory Pathway
- Encourage Coverage by Health Plans, Employers, and Medicare
- Promote Clinician Adoption
|
|
7
|
|
|
8
|
- Half of all Americans with diabetes are not achieving recommended
diabetes targets
- A recent study of people intensively managing their diabetes (testing
nine time a day) had shocking results:
- Less than 30% of the day in normal glucose range
- More than 70% of day in high or low glucose ranges
|
|
9
|
- Continuous glucose monitors (CGM) give patients new tools with which to
control diabetes
- Continuous readings – see effects of insulin, food, exercise
- Trends – information to ward off highs and lows
- Alarms – alert patient or family member
- Two models approved by FDA, one pending
- Not routinely covered by health plans
- New to many doctors and health care providers
|
|
10
|
- Recent studies have found significant results for people with diabetes
using continuous glucose monitors:
- Reductions in A1c
- Reductions in hypoglycemia
- Increases in time spent in target range
- Benefits in children and adults
- But CGM not sufficient
- Not all patients will respond to CGM data
- Even model patients can’t respond 24/7
|
|
11
|
|
|
12
|
|
|
13
|
|
|
14
|
|
|
15
|
|
|
16
|
|
|
17
|
|
|
18
|
|
|
19
|
|
|
20
|
|
|
21
|
|
|
22
|
|
|
23
|
|
|
24
|
|
|
25
|
|
|
26
|
|
|
27
|
|
|
28
|
|
|
29
|
|
Notes
